drugset / Trial / NCT07336147
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
Add-on dostarlimab to chemoradiation with etoposide and cisplatin and radiotherapy can improve progression-free survival (PFS) compared with historical controls who were treated with chemoradiation alone in SCNECC
Timeline
- Start
- 2025-12-22
- Primary completion
- 2027-12-22
- Completion
- 2030-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dostarlimab | Monoclonal antibody | 500 mg | — |
Indications
No indication recorded.